AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Trial: NCT00259922
Drug: Alvimopan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg QD
Trial: NCT00259922
Drug: Alviompan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg BID
Trial: NCT00677443
Drug: S-1 & Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
Trial: NCT04111159
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
Trial: NCT00296790
Drug: zolpidem tartrate
RxNorm normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Trial: NCT03656198
Drug: Sterile Water Injection
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Trial: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Trial: NCT00079911
Drug: valacyclovir hydrochloride
RxNorm normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valacyclovir hydrochloride
Trial: NCT02986607
Drug: parathyroid hormon 1-84
RxNorm normalized name: Parathyroid hormone (1-84) human recombinant
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
Trial: NCT02209012
Drug: Topical Solution Vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle PDT given in CP0108
Trial: NCT00900757
Drug: Palonosetron (PALO)
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
Trial: NCT03837964
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01846221
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
Trial: NCT01609166
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 3% cream application in one side of the body, twice a day for 6 months
Trial: NCT01668966
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
Trial: NCT00861874
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 IV, Days 1-5
Trial: NCT00861874
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
Trial: NCT01947491
Drug: Vehicle Lotion
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01947491
Drug: Vehicle Spray
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03320850
Drug: OnabotulinumtoxinA and Hydrogel admixture
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
Trial: NCT00327743
Drug: larotaxel
RxNorm normalized name: Larotaxel
DrugBank: Larotaxel (DB12984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion on Day 1 of a 21-day cycle
Trial: NCT02768441
Drug: Dexamphetamine
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
Trial: NCT00724009
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
Trial: NCT03091881
Drug: Granisetron 0.1 MG/ML
RxNorm normalized name: granisetron 0.1 MG/ML
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 0.1 MG/ML Will be given 10 min before spinal block
Trial: NCT01670734
Drug: alirocumab SAR236553 (REGN727)
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous
Trial: NCT04178642
Drug: percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
Trial: NCT02031640
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02031640
Drug: Albuterol/salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
Trial: NCT02205008
Drug: Early postoperative intraperitoneal chemothgerapy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq
Trial: NCT03184584
Drug: PBI-4050
RxNorm normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 200 mg capsules (800 mg total) administered orally, once daily
Trial: NCT00571701
Drug: celebrex (celecoxib)
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight \>25 kg
Trial: NCT05158426
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anesthesia induction is initiated with intravenous infusion propofol at 1.5µg/ml, and increased 0.5µg/ml every 3min until OAA/S score 0.
Trial: NCT00446576
Drug: Epoetin Alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02067663
Drug: Mirena
RxNorm normalized name: Mirena
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The IUD will be placed as part of standard clinical care.
Trial: NCT03086226
Drug: Fosravuconazole
RxNorm normalized name: Fosravuconazole
DrugBank: Fosravuconazole (DB15204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
Trial: NCT03086226
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This will be the active comparator
Trial: NCT01747538
Drug: Dose 1 gevokizumab
RxNorm normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT01747538
Drug: Dose 2 gevokizumab
RxNorm normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT00704444
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe, 10-mg tablets
Trial: NCT00704444
Drug: Ezetimibe + other lipid-lowering medication(s)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
Trial: NCT00525616
Drug: Mabthera
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two IV perfusions of 1000mg at 15 days intervals
Trial: NCT03960866
Drug: Phentolamine Mesylate Ophthalmic Solution 1%
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Sterile Ophthalmic Solution
Trial: NCT02634788
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine sublingual spray delivered via single 100 μL spray
Trial: NCT00691132
Drug: phenethyl isothiocyanate
RxNorm normalized name: Phenethyl Isothiocyanate
DrugBank: Phenethyl Isothiocyanate (DB12695)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00487240
Drug: Insulin Lispro Protamine Suspension
RxNorm normalized name: Insulin Lispro Protamine Suspension and Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
Trial: NCT00487240
Drug: Insulin Levemir
RxNorm normalized name: insulin detemir Injectable Solution [Levemir]
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
Trial: NCT02892422
Drug: Lu AF35700
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study